Drug Trial Radar · NCT01930708
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Last checked: Nov 20, 2026Latest source record: Mar 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,114
Actual
Start
Oct 31, 2013
Primary completion
Mar 31, 2016
Study completion Jan 9, 2020
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Aug 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period. The secondary objectives of this study in this population are to assess the impact of DMF over a 12-month period on participants -reported health-related quality of life (HRQoL) outcomes, additional clinical effectiveness outcomes, and health economics-related outcomes, and to characterize participants-reported adherence to DMF.
Conditions
- Relapsing-Remitting Multiple Sclerosis
- Multiple Sclerosis
Interventions
dimethyl fumarateDrug
Administered as per the approved dosage in all countries where DMF has received marketing authorization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: 12 Months
Locations
90 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Innsbruck, Austria
Research Site
Klagenfurt, Austria
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Sankt Pölten, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Villach, Austria
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Melsbroek, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Saint John's, New Brunswick, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
London, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Brno, Czechia
Research Site
Havířov, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Olomouc, Czechia
Research Site
Pardubice, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Nancy, France
Research Site
Rouen, France
Research Site
Strasbourg, Bas Rhin, France
Research Site
Dijon, Cote dÝOr, France
Research Site
Besançon, Doubs, France
Research Site
Nîmes, Gard, France
Research Site
Bordeaux, Gironde, France
Research Site
Colmar, Haut Rhin, France
Research Site
Toulouse, Haute Garonne, France
Research Site
Limoges, Haute Vienne, France
Research Site
Rennes, Ille Et Vilaine, France
Research Site
Grenoble, Isere, France
Research Site
Nantes, Loire Atlantique, France
Research Site
Reims, Marne, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.